Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

JAMA Oncology

Volumn 5, Issue 2, 2019, Pages 195-203

  Siu, Lillian L ^a   Even, Caroline ^b   Mesía, Ricard ^c   Remenar, Eva ^d   Daste, Amaury ^e   Delord, Jean Pierre ^f   Krauss, Jürgen ^g   Saba, Nabil F ^h   Nabell, Lisle ⁱ   Ready, Neal E ^j   Braña, Irene ^k   Kotecki, Nuria ^l   Zandberg, Dan P ^m   Gilbert, Jill ⁿ   Mehanna, Hisham ^o   Bonomi, Marcelo ^p   Jarkowski, Anthony ^q,r   Melillo, Giovanni ^q   Armstrong, Jon M ^q   Wildsmith, Sophie ^q   Fayette, Jérôme ^s   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

^d NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^e HÔPITAL SAINT ANDRÉ   (France)

^f institut universitaire du cancer Toulouse Oncopole   (France)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l CENTRE OSCAR LAMBRET   (France)

^m UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁿ Henry Joyce Cancer Clinic   (United States)

^o UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^p OHIO STATE UNIVERSITY   (United States)

^q ASTRAZENECA   (United Kingdom)

^r BRISTOL MYERS SQUIBB   (United States)

^s UNIVERSITÉ DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DURVALUMAB; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 LIGAND 1; TAXANE DERIVATIVE; TICILIMUMAB; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ARTICLE; ASIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EUROPE; FATIGUE; FEMALE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NORTH AMERICA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; HEAD AND NECK TUMOR; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; B7-H1 ANTIGEN; EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85056089888     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.4628     Document Type: Article

References (37)

1. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 2002; 13 (7): 995-1006. doi: 10.1093/annonc/mdf172 12176777
2. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010; 21 (suppl 7): vii252-vii261. doi: 10.1093/annonc/mdq453 20943624
3. Kushwaha VS, Gupta S, Husain N, Gefitinib, methotrexate and methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. Cancer Biol Ther. 2015; 16 (2): 346-351. doi: 10.4161/15384047.2014.961881 25756517
4. Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009; 27 (11): 1864-1871. doi: 10.1200/JCO.2008.17.0530 19289630
5. Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25 (16): 2171-2177. doi: 10.1200/JCO.2006.06.7447 17538161
6. Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol. 2007; 37 (7): 477-481. doi: 10.1093/jjco/hym059 17720737
7. Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel). 2015; 7 (4): 2397-2414. doi: 10.3390/cancers7040900 26690220
8. Keck MK, Zuo Z, Khattri A, Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015; 21 (4): 870-881. doi: 10.1158/1078-0432.CCR-14-2481 25492084
9. KEYTRUDA® (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2017.
10. OPDIVO (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2017.
11. Segal NH, Ou S-HI, Balmanoukian AS, Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort [abstract 949O]. Ann Oncol. 2016; 27 (suppl 6): 328-350. doi: 10.1093/annonc/mdw376.01
12. Zandberg D, Algazi A, Jimeno A, Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Paper presented at ESMO; September 8-12, 2017; Madrid, Spain.
13. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366 (26): 2443-2454. doi: 10.1056/NEJMoa1200690 22658127
14. Herbst RS, Soria JC, Kowanetz M, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515 (7528): 563-567. doi: 10.1038/nature14011 25428504
15. Antonia S, Goldberg SB, Balmanoukian A, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016; 17 (3): 299-308. doi: 10.1016/S1470-2045(15)00544-6 26858122
16. Rebelatto MMA, Sabalos C, Walker J, Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. J Clin Oncol. 2015; 33 (15)(suppl): 8033-8033. doi: 10.1200/jco.2015.33.15-suppl.8033
17. Segal NH, Hamid O, Hwu W, A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data. Presented as a poster at: ESMO; September 26-30, 2014; Madrid, Spain. Poster 1058PD.
18. Wildsmith S, Scott M, Midha A, PD-L1 expression in patients screened for phase 2 head an neck squamous cell carcinoma clinical studies (HAWK and CONDOR). Paper presented at: AACR Annual Meeting; April 14-17, 2018; Chicago, IL.
19. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107 (9): 4275-4280. doi: 10.1073/pnas.0915174107 20160101
20. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010; 33 (3): 225-235. doi: 10.1097/CJI.0b013e3181c01fcb 20445343
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12 (4): 252-264. doi: 10.1038/nrc3239 22437870
22. Wolchok JD, Kluger H, Callahan MK, Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369 (2): 122-133. doi: 10.1056/NEJMoa1302369 23724867
23. Ribas A, Camacho LH, Lopez-Berestein G, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23 (35): 8968-8977. doi: 10.1200/JCO.2005.01.109 16204013
24. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013; 5 (3): 215-229. doi: 10.2217/imt.13.9 23444951
25. Balar AV, Mahipal A, Grande E, Durvalumab + tremelimumab in patients with metastatic urothelial cancer. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research. Chicago, IL: AACR; 2018:78(13)(suppl):CT112-CT112. doi: 10.1158/1538-7445.AM2018-CT112
26. Kirkwood JM, Lorigan P, Hersey P, Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010; 16 (3): 1042-1048. doi: 10.1158/1078-0432.CCR-09-2033 20086001
27. Ribas A, Kefford R, Marshall MA, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31 (5): 616-622. doi: 10.1200/JCO.2012.44.6112 23295794
28. US Dept of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03/Archive/CTCAE-4.0-2009-05-29-QuickReference-8.5x11.pdf. Published May 28, 2009. Accessed October 1, 2018.
29. Cohen EE, Harrington KJ, Le Tourneau C, Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial [abstract]. Ann Oncol. 2017; 28 (suppl 5): 28. doi: 10.1093/annonc/mdx440
30. Ferris RL, Blumenschein G Jr, Fayette J, Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375 (19): 1856-1867. doi: 10.1056/NEJMoa1602252 27718784
31. Bauml J, Seiwert TY, Pfister DG, Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017; 35 (14): 1542-1549. doi: 10.1200/JCO.2016.70.1524 28328302
32. Soulieres D, Cohen E, LeTourneau C, Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. In: Proceedings of the 109th Annual Meeting of the American Association for Cancer Research (AACR). Chicago, IL; AACR; 2018.
33. Ferris RL, Blumenschein G Jr, Fayette J, Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81: 45-51. doi: 10.1016/j.oraloncology.2018.04.008 29884413
34. Larkin J, Chiarion-Sileni V, Gonzalez R, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373 (1): 23-34. doi: 10.1056/NEJMoa1504030 26027431
35. Romano E, Kusio-Kobialka M, Foukas PG, Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015; 112 (19): 6140-6145. doi: 10.1073/pnas.1417320112 25918390
36. Chow LQM, Haddad R, Gupta S, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016; 34 (32): 3838-3845. doi: 10.1200/JCO.2016.68.1478 27646946
37. Seiwert TY, Burtness B, Mehra R, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016; 17 (7): 956-965. doi: 10.1016/S1470-2045(16)30066-3 27247226